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Abstract
Background: The interaction between overweight/obesity and alcohol intake on liver enzyme concentrations have
been demonstrated. No studies have yet examined the interaction between metabolic syndrome or multiple
metabolic risk factors and alcohol intake on liver enzymes. The aim of this study was to examine if alcohol
consumption modifies the effect of metabolic risk on elevated serum GGT in Indigenous Australians.
Methods: Data were from N = 2609 Indigenous Australians who participated in a health screening program in
rural far north Queensland in 1999-2000 (44.5% response rate). The individual and interactive effects of metabolic
risk and alcohol drinking on elevated serum GGT concentrations (≥50 U/L) were analyzed using logistic regression.
Results: Overall, 26% of the population had GGT≥50 U/L. Elevated GGT was associated with alcohol drinking
(moderate drinking: OR 2.3 [95%CI 1.6 - 3.2]; risky drinking: OR 6.0 [4.4 - 8.2]), and with abdominal obesity (OR 3.7
[2.5 - 5.6]), adverse metabolic risk cluster profile (OR 3.4 [2.6 - 4.3]) and metabolic syndrome (OR 2.7 [2.1 - 3.5]) after
adjustment for age, sex, ethnicity, smoking, physical activity and BMI. The associations of obesity and metabolic
syndrome with elevated GGT were similar across alcohol drinking strata, but the association of an adverse
metabolic risk cluster profile with elevated GGT was larger in risky drinkers (OR 4.9 [3.7 - 6.7]) than in moderate
drinkers (OR 2.8 [1.6 - 4.9]) and abstainers (OR 1.6 [0.9 - 2.8]).
Conclusions: In this Indigenous population, an adverse metabolic profile conferred three times the risk of elevated
GGT in risky drinkers compared with abstainers, independent of sex and ethnicity. Community interventions need
to target both determinants of the population’s metabolic status and alcohol consumption to reduce the risk of
elevated GGT.
Background
Non-alcoholic fatty liver disease (NAFLD) has become
the most common cause of chronic liver disease and
cryptogenic cirrhosis in developed countries. The
increasing prevalence of obesity, type 2 diabetes, and
metabolic syndrome may be important drivers of
increasing rates of NAFLD diagnoses [1]. An elevated
serum gamma-glutamyl transferase (GGT) has been
demonstrated as a biomarker of NAFLD [2] and,
although it is not the only marker of chronic liver dis-
ease, it does predict future diabetes, coronary heart dis-
ease and stroke [3,4].
The Australian indigenous population has an excess of
metabolic syndrome and type 2 diabetes relative to the
non-indigenous population [5-7]. BMI-specific incidence
rates for type 2 diabetes in Australian Aboriginal adults
are among the highest in the world [8]. The overall inci-
dence rate in rural Far North Queensland indigenous
communities from 2000 to 2006 was 29 per 1000 person
years (predicted to equate to 120 new diabetes diagnoses
per year) [9]. Diabetes and CVD account for 7% and
14%, respectively of the overall burden of disease in
Indigenous Australians, and for 12% and 24% respec-
tively, of the health gap between indigenous and non-
indigenous Australians [10].
Heavy and moderate drinkers are more likely to have
elevated serum GGT when compared to abstainers [11].
The metabolic effects of alcohol include an increase in
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conversion of acetyl CoA to triglycerides (TG) which are
secreted into the blood as very low density lipoproteins
(VLDLs); ectopic fat accumulation in the liver from
excess TG production and a rise in GGT and other liver
enzymes; and weight gain from energy derived from
alcohol (about 29 kj/gram) [12]. Alcohol accounted for
5% of the total Indigenous burden of disease, similar to
high cholesterol and blood pressure, and for 4% in the
health gap with non-indigenous Australians [10].
Li et al. reported elevated GGT with obesity, meta-
bolic syndrome and physical inactivity in Indigenous
non-drinkers in this cohort [13]. Little work has been
published on NAFLD or alcohol-related liver disease in
Indigenous populations worldwide. It is not known
whether the additive effects of body fatness and alcohol
intake on serum liver enzymes described in Nordic
populations [14,15] apply to Indigenous Australians or
whether drinking combined with multiple metabolic risk
factors (or metabolic syndrome) further increases risk of
elevated liver enzymes.
Evidence suggests that Aboriginal people have a
greater risk of coronary heart disease events than would
be expected based on Framingham risk functions [16].
Similar underestimation of risk using these algorithms
has been reported in ethnic minorities in the UK [17]
with overestimated risk in other ethnic groups [18,19].
Moreover, normative values for waist circumference
have not been established for Aboriginal and Torres
Strait Islanders (TSI) and these populations differ in a
number of metabolic characteristics, relative to fatness
[7,20,21]. Due to this uncertainty, we defined population
metabolic profiles using cluster analysis and then com-
pared the alcohol stratified effects of metabolic risk clus-
ter versus International Diabetes Federation (IDF)
classified metabolic syndrome on elevated GGT.
Methods
Population
Subjects were participants in The Well Person’s Health
Check [22]. Briefly, in 1999 - 2000, all indigenous resi-
dents aged 13 years and older, in 23 far north Queens-
land rural communities, were invited to participate
through printed media, local radio, and word of mouth
via the local health service, community council and
community groups. A total of 3811 (participation rate
44.5%) participated in the study. The cohort was demo-
graphically representative of the indigenous population
of the local area when compared to local population
census data. Aboriginal and TSI are recognized as dis-
tinct ethnic groups and ascertainment of ethnicity was
by self-identification in a manner consistent with Aus-
tralian national minimum dataset specifications [23].
After exclusion of children under age 15 (N = 496),
non-indigenous (N = 482) and individuals reporting
joint Aboriginal-TSI descent (N = 224), a total of 2609
participants were included in this analysis. All partici-
pants provided informed consent to take part in the
study. The study procedures were in accordance with
the ethical standards on human research and thereby
approved by the Cairns Base Hospital Human Research
Ethics Committee with support from the peak Indigen-
ous Health Organizations, Apunipima Cape York Health
Council and the Torres Strait and Northern Peninsula
Area Health Council.
Data Collection
Height to the nearest 0.1 centimeter (cm) and weight to
the nearest 0.1 kilogram (Kg) were measured in partici-
pants without shoes and wearing only light clothing.
Body mass index (BMI) was calculated (weight (kg)/
height (m2)). Waist circumference was measured mid-
way between the lower border of the rib cage and the
top of the iliac crest and recorded to the nearest 0.1
centimeter. Data were collected on self-reported medical
conditions and none reported known liver disease. Phy-
sical activity was measured using a 7-day recall method
in which the participants were asked to report daily phy-
sical activities of at least moderate intensity, lasting at
least 30-minutes, performed during the week before
their health check. Physical activity level was defined by
American Heart Association criteria in which “active”
reflects moderate to vigorous physical activity for at
least 30-minutes per day on 5 days in the week before
the survey [24]. Smoking behaviour was collected by
standard questionnaire. The amount of alcohol con-
sumed over a week was collected by 7-day recall diary
and converted to number of standard drinks per week
(1 standard drink = 10 grams of alcohol). Risky alcohol
drinking was defined as greater than 6 standard drinks
on any occasion or greater than 4 standard drinks per
day in the recall week for males and greater than 4
drinks on any occasion or greater than 2 drinks per day
in females [22,25].
Three seated blood pressure measurements were
taken at 2 minute intervals after 10 minutes rest using
a Dinamap automated oscillometric device (Critikon
Corporation, USA) and the average was used in all
analyses. Venous blood was sampled in the morning
after an 8-hour fast as previously described [22]. GGT
was measured using the kinetic photometric procedure
with Cobas Integra 800 (Roche Diagnostics, USA).
Blood glucose and lipids were measured using photo-
metric enzyme endpoint assay with Cobas Integra 700/
400 (Roche Diagnostics, USA).
The outcome variable, GGT, was classified as normal
(<50 U/L) or elevated (≥50 U/L) based on laboratory
specific reference ranges (Queensland Pathology Service,
http://www.health.qld.gov.au/qhcss/qhps/default.asp).
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Metabolic syndrome was defined according to the IDF
definition of waist circumference (Europid cut-offs:
≥94 cm for men or ≥80 cm for women) plus any two of
the following: raised triglycerides (≥1.7 mmol/L);
reduced HDL cholesterol (< 1.03 mmol/L for men or
< 1.29 mmol/L for women); raised blood pressure
(≥130 mmHg for systolic or ≥85 mmHg for diastolic);
and raised fasting plasma glucose (≥5.6 mmol/L) [26].
Specific treatment for lipid abnormalities or previously
diagnosed hypertension and previously diagnosed T2DM
were not used in classification.
Waist circumference was used as a continuous
variable and also to classify abdominal overweight and
obesity, using World Health Organization (WHO) gen-
der-specific criteria: overweight was ≥80 cm in women
and ≥94 cm in men; obesity was ≥88 cm in women and
≥102 cm in men; < 80 cm in women and < 94 cm in
men was classified as normal. BMI was used as a contin-
uous variable and also to classify generalized overweight
and obesity: < 25 Kg/m2 (normal); 25-29.9 Kg/m2 (over-
weight) and ≥30 Kg/m2 (obesity) [27]. Diabetes was
determined by clinical diagnosis of diabetes, verified by
participants’ medical records, or 2 hour glucose toler-
ance test or fasting blood glucose ≥7.0 mmol/L [28].
Blood pressure, fasting triglycerides, total cholesterol,
HDL and glucose were used as continuous variables in
all analyses.
Derivation of the metabolic risk factor cluster variable
(MR cluster)
Cluster Analysis is the process of assigning members of
a population into groups such that the members of each
group share common characteristics. The method is an
example of unsupervised learning. There is no a priori
assumption made about what the groups represent or
indeed the number of groups. Expectation Maximisation
(EM) cluster analysis was applied to standardized (mean
centred) variables: waist circumference, TG, HDL, systo-
lic and diastolic blood pressure and fasting glucose, and
was performed in STATISTICA (data analysis software
system), version 8.0 (StatSoft, Inc. (2007) http://www.
statsoft.com). To determine the major contributing vari-
ables to cluster membership, partial least squares (PLS)
was applied since the predictors (the original variables)
are highly correlated and so ordinary multinomial
regression is inaccurate due to multicollinearity. Detail
on both EM cluster analysis and PLS can be found in
Additional file 1.
Statistical Analysis
A priori it was expected that Aboriginal and TSI people
would differ significantly in their anthropometric and
metabolic characteristics, so comparisons for all vari-
ables were made across Aboriginal versus TSI ethnicity.
Comparisons were also made for all variables across
normal versus elevated GGT. Comparative analyses
were by Chi-squared tests for categorical variables,
independent t-tests for normally distributed continuous
variables or Mann-Whitney rank-sum tests for non-
normally distributed continuous variables. Unadjusted
comparisons between MR clusters were analyzed using
independent samples t-tests for continuous variables
and Chi-squared analysis with Fisher’s exact test for
categorical variables. Logistic regression models were
built to determine the associations (log odds) of drink-
ing, metabolic syndrome and MR cluster with elevated
GGT (≥50 U/L) for the whole population and stratified
by ethnicity and sex. Similarly, odds ratios for the asso-
ciation of abdominal obesity, BMI categories, metabolic
syndrome and MR cluster with elevated GGT, were cal-
culated for the whole population and stratified by drink-
ing status. Separate logistic regression models were built
to examine the effect on elevated GGT of interactions
between drinking and: sex; ethnicity; overweight and
obesity defined by BMI and waist circumference; and
metabolic risk defined by IDF MetS criteria and MR
cluster. Models were adjusted for age, sex, ethnicity,
BMI, smoking and physical activity levels where appro-
priate. Data analyses were performed using STATA ver-
sion 10.1 (STATA Corp, College Station, Texas, USA).
Results
Participants with missing data on serum GGT (N = 76)
were not different in age, sex, BMI, metabolic profile or
lifestyle behaviours than those with GGT data. Those
missing information regarding metabolic syndrome (N =
224) were not different in age, sex, BMI, and lifestyle
behaviours but had lower mean BP than those with
complete metabolic syndrome information (125.5 ± 18.4
v 130.4 ± 19.6 mmHg, P < 0.001). Those missing
records of drinking (N = 83) tended to be older (43.2 ±
17.6 v 37.2 ± 15.3 years, P < 0.001) and more likely to
be female (65.1% v 51.4%, P = 0.014).
Table 1 describes the metabolic and behavioral char-
acteristics of the cohort by Aboriginal and TSI status
and sex. In both sexes, the TSI population had a signifi-
cantly lower prevalence of elevated GGT, a higher pre-
valence of obesity, type 2 diabetes, metabolic syndrome
and physically active people, and a lower proportion of
smokers and drinkers, when compared with the Aborigi-
nal population (all Ps < 0.05). Waist circumference,
BMI, SBP and fasting glucose were higher and GGT and
triglycerides were lower in TSI when compared with
Aboriginal people (all Ps < 0.05). The prevalence of
adverse MR cluster was significantly greater in TSI
when compared to Aboriginal men, but was similar in
women.
Table 2 describes the demographic, behavioral and
metabolic characteristics of the cohort by normal and
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Table 1 Metabolic and behavioral characteristics of the study population, by ethnicity and sex
Aboriginal (n = 1641) TSI (n = 968) Overall (N = 2609)
Mean or No. 95% CI Mean or No. 95% CI Mean or No.
Female N = 881 N = 471
Age, years (SD) 37.4 (15.5) 36.4- 38.4 38.3 (16.0) 36.9-39.75 37.7 (15.7)
WC, cm (SD) * 92.2 (16.5) 91.1- 93.3 103.6 (15.6) 102.1-105.1 96.2 (17.4)
BMI, kg/m2 (SD)* 25.5 (6.6) 25.2-25.9 31.0 (6.7) 30.5-31.4 27.6 (7.1)
SBP, mmHg (SD)* 125.5 (17.0) 124.1-126. 9 130.3 (16.1) 128.4-132.3 127.2 (21.3)
DBP, mmHg (SD)* 69.7 (13.5) 68.8-70.6 67.8 (12.2) 66.7-68.9 69.0 (13.1)
T Chol, mmol/L (SD) 4.8 (1.0) 4.7- 4.82 4.8 (1.0) 4.75- 4.9 4.8 (1.0)
HDL, mmol/L (SD) * 1.16 (0.3) 1.14-1.18 1.11 (0.2) 1.09-1.13 1.1 (0.3)
GGT, U/L (SD) * 39.2 (47.1) 36.0-42.4 27.2 (21.1) 25.3-29.1 35.0 (40.4)
FPG, mmol/L (SD)* 5.5 (2.5) 5.4-5.7 6.2 (3.1) 5.9-6.5 5.8 (2.7)
Trigs, mmol/L (SD)‡* 1.7 (1.2) 1.6-1.73 1.5 (1.1) 1.4- 1.6 1.6 (1.1)
Abdominal obesity † (%)*
Normal 205 (23.6) 20.5-26.1 43 (9.1) 6.5-11.7 248 (18.5)
Overweight 158 (18.2) 15.4-20.4 40 (8.5) 6.0-11.0 198 (14.8)
Obesity 507 (58.3) 55.5-62.1 388 (82.4) 78.9-85.8 895 (66.7)
BMI (%)*
<25 405 (46.0) 42.7-49.3 76 (16.1) 12.8-19.5 481 (35.6)
25-30 237 (26.9) 24.0-29.8 109 (23.1) 19.3-27.0 346 (25.6)
30+ 239 (27.1) 24.2-30.1 286 (60.7) 48.8-55.1 525 (38.8)
Smokers (%)* 490 (56.0) 52.7-59.3 211 (44.8) 40.3-49.3 701 (52.1)
Drinking (%) * 526 (62.4) 59.2-65.7 233 (51.1) 46.5-55.7 759 (58.5)
Risky drinking † (%) * 356 (67.7) 63.7-71.7 112 (48.1) 41.6-54.5 468 (61.7)
Physically active † (%)* 164 (18.6) 16.0-21.2 117 (24.8) 20.9-28.7 281 (20.8)
GGT ≥50 U/L (%) * 181 (21.2) 18.4-23.9 36 (7.8) 5.4-10.3 217 (16.5)
Diabetes (%)* 114 (12.9 ) 10.7-15.2 107 (22.7) 18.9-26.5 221 (16.4)
Metabolic syndrome † (%) * 353 (40.1) 36.9-43.4 246 (52.2) 47.7-56.7 595 (44.3)
Adverse MR cluster profile † (%) 268 (34.3) 31.0-37.6 171(37.7) 33.2-42.1 439 (35.6)
Male N = 760 N = 497
Age, years (SD) 36.6(14.9) 35.5-37.7 37.5 (15.2) 36.2-38. 9 37.0 (15.1)
WC, cm (SD) * 89.7 (14.6) 88.7-90.8 100.7 (15.0) 99.4-102.1 94.1 (15.7)
BMI, kg/m2 (SD)* 24.5 (5.6) 24.1-24.9 29.8 (5.8) 29.2-30.3 26.6 (6.2)
SBP, mmHg (SD)* 130.8 (19.5) 129.6-132.0 136.3 (19.1) 134.8-137.7 130.0 (16.9)
DBP, mmHg (SD) 74.2 (13.8) 73.2-75.2 73.4 (13.1) 72.3-74.6 73.9 (13.5)
T Chol, mmol/L (SD)* 5.0 (1.1) 4.9- 5.04 5.2 (1.0) 5.1- 5.3 5.1 (1.1)
HDL, mmol/L (SD) * 1.2 (0.4) 1.17-1.22 1.1 (0.3) 1.102-1.15 1.2 (0.3)
GGT, U/L (SD) * 71.0 (85.6) 64.8-77.3 46.0 (49.2) 41.6-50.4 61.0 (74.2)
FPG, mmol/L (SD)* 5.4 (2.1) 5.2-5.5 6.0 (2.8) 5.7-6.2 5.6 (2.4)
Trigs, mmol/L (SD)‡* 2.1 (1.9) 2.0- 2.2 1.9 (1.4) 1.7-2.0 2.0 (1.8)
Abdominal obesity † (%)*
Normal 486 (64.1) 60.5-67.4 156 (31.5) 27.3-35.5 642 (51.2)
Overweight 130 (17.2) 14.4-19.9 111 (22.4) 18.7-26.0 241 (19.2)
Obesity 142(18.7) 16.2-21.7 228 (46.1) 78.9-85.8 370 (29.5)
BMI (%)*
<25 856 (52.2) 49.7-54.6 178 (18.4) 15.9-20.8 1034 (39.6)
25-30 417 (25.4) 23.3-27.5 287 (29.7) 26.8-32.5 704 (27.0)
30+ 368 (22.4) 20.4-24.4 503 (52.0) 48.8-55.1 871 (33.4)
Smokers (%)* 516 (68.8) 65.5-72.1 274 (55.5) 51.1-59.9 1491 (57.6)
Drinking (%) * 607 (82.3 ) 79.5-85.0 369 (75.3) 71.5-79.1 976 (79.5)
Haren et al. BMC Public Health 2010, 10:454
http://www.biomedcentral.com/1471-2458/10/454
Page 4 of 10
Table 2 Demographic and health risk factor status, by GGT category in Indigenous adults
GGT<50 U/L (n = 1876) GGT≥50 U/L (n = 657) P*
Mean or No. 95% CI No. (%) 95% CI
Age (Years) (SD) 36.6 (16.3) 35.8-37.3 39.3 (12.5) 38.4- 40.2 <0.01
Male (%) 779 (41.5) 39.3-43.8 440 (67.0) 63.4-70.6 <0.01
Aborigines (%) 1093 (58.3) 56.0-60.5 493 (75.0) 71.7-78.4) <0.01
WC (SD) 94.3 (17.2) 93.5- 95.1 97.4 (14.5) 96.3-98.5 <0.01
Abdominal obesity (%) † 0.09
Normal 655 (34.9) 32.8-37.1 208 (31.7) 28.1-35.2
Overweight 300 (16.0) 14.3-17.7 127 (19.3) 16.3-22.4
Obesity 921 (49.1 ) 46.8-51.4 322 (49.1) 45.2-52.8
BMI (SD) 27.5 (7.2) 27.2- 27.9 27.5 (6.5) 27.0- 28.0 0.45
BMI 0.01
<25 760 (40.5) 38.3-42.7 244 (37.1) 33.4-40.8
25-30 480 (25.6) 23.6-27.6 207 (31.5) 28.0-35.1
30+ 636 (33.9) 31.8-36.0 206 (31.4) 27.8-34.9
SBP (SD) 128.2 (19.7) 127.3-129.1 135.4 (18.4) 134.0-136.8 <0.01
DBP (SD) 69.4 (13.1) 68.8-70.0 77.3 (13.2) 76.3- 78.3 <0.01
HDL (SD) 1.14 (0.3) 1.13-1.15 1.19 (0.4) 1.16-1.22 <0.01
Smoking (%) 982 (52.7) 50.4-55.0 460 (70.5) 66.9-73.9 <0.01
Drinking (%) 1117 (61.7) 59.5-64.0 565 (87.7) 85.2-90.3 <0.01
Risky drinking † (%) * 679 (60.8) 57.9-6365 466 (82.5) 79.3-85.6 <0.01
Physically active † 467 (24.9) 22.9-26.9 130 (19.8) 16.7-26.8 0.01
FPG (SD) 5.5 (2.5) 5.4-5.6 6.2 (2.9) 5.9- 6.4 <0.01
Diabetes (%) 236 (12.6) 11.1-14.1 133 (20.2) 17.2-23.3 <0.01
Trigs (SD) ‡* 1.5 (1.1) 1.4-1.52 2.7 (2.0) 2.5- 2.8 <0.01
Metabolic syndrome (%) † 683 (36.4) 34.2-38.6 346 (52.6) 48.8-56.5 <0.01
Adverse MR Cluster profile (%) † 570 (32.8) 30.6-35.0 384 (60.0) 56.2-63.8 <0.01
*significant difference of <0.05 between normal (<50 U/L) and elevated (≥50 U/L) GGT, using Chi square tests for categorical variables, t-test (for continuous
variables with normal distribution, and Mann-Whitney rank-sum test for continuous variables with non-normal distribution‡. † Abdominal obesity defined using
WHO WC gender specific criteria: overweight being WC of 80-88 cm in females and 94-102 cm in males, while obesity being WC ≥88 cm in females and 102 cm
in males. Risky drinking was defined as > 6 drinks on any occasion or >4 drinks per day in males and >4 drinks on any occasion or >2 drinks per day in female
in the week prior to the survey. Physically active, defined by American Heart Association criteria in which “active” means doing moderate to vigorous physical
activity for more than 30 min per day for 5 days in the week before the survey. Metabolic syndrome defined by IDF criteria: waist circumference (≥94 cm in
males and ≥80 for females), raised triglycerides (≥1.7 mmol/L), reduced HDL (<1.03 in males or <1.29 in females), raised blood pressure (systolic >130 mmHg or
diastolic≥85 mmHg), and plasma glucose (≥5.6 mmol/L). Adverse MR (metabolic risk) cluster profile was obtained by EM cluster analysis. WC is waist
circumference, Trigs is serum triglycerides, SBP is systolic blood pressure, DBP is diastolic blood pressure, HDL is high density lipoprotein cholesterol, FPG is
fasting plasma glucose.
Table 1 Metabolic and behavioral characteristics of the study population, by ethnicity and sex (Continued)
Risky drinking † (%) * 485 (79.9) 76.7-83.1 230 (62.3) 57.4-67.3 715 (73.3)
Physically active † (%)* 163 (21.4) 18.5-24.4 168 (33.8) 29.6-38.0 331 (26.3)
GGT ≥50 U/L (%) * 312 (42.7) 39.1-46.3 128 (26.2) 22.3-30.1 440 (36.1)
Diabetes (%)* 72 (9.5) 7.3-11.6 83 (16.7) 13.4-20.0 155 (12.3)
Metabolic syndrome † (%) * 199 (26.2) 23.1-29.3 232 (46.7) 42.3-56.1 431 (34.3)
Adverse MR cluster profile † (%) * 275 (40.8) 37.1-44.5 241 (50.6) 46.1-55.1 516 (44.9)
*significant difference of <0.05 between Aboriginal and TSI, using Chi square tests for categorical variables, t-test (for continuous variables with normal
distribution, and Mann-Whitney rank-sum test for continuous variables with non-normal distribution‡. † Abdominal obesity defined using WHO WC gender
specific criteria: overweight being WC of 80-88 cm in females and 94-102 cm in males, while obesity being WC ≥88 cm in females and 102 cm in males. Risky
drinking was defined as > 6 drinks on any occasion or >4 drinks per day in males and >4 drinks on any occasion or >2 drinks per day in female in the week
prior to the survey. Physically active, defined by American Heart Association criteria in which “active” means doing moderate to vigorous physical activity for
more than 30 min per day for 5 days in the week before the survey. Metabolic syndrome defined by IDF criteria: waist circumference (≥94 cm in males and ≥80
for females), raised triglycerides (≥1.7 mmol/L), reduced HDL (<1.03 in males or <1.29 in females), raised blood pressure (systolic >130 mmHg or diastolic≥85
mmHg), and plasma glucose (≥5.6 mmol/L). Adverse MR (metabolic risk) cluster profile was obtained by EM cluster analysis. WC is waist circumference, Trigs is
serum triglycerides, SBP is systolic blood pressure, DBP is diastolic blood pressure, HDL is high density lipoprotein cholesterol, FPG is fasting plasma glucose.
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elevated GGT. The overall prevalence of elevated GGT
was 25.9%. In this group, people were older, more likely
to be male, Aboriginal, obese, smokers, drinkers, dia-
betic, be classified as metabolic syndrome, have an
adverse MR cluster profile, and be physically inactive,
when compared to those with normal GGT.
The MR cluster profile of the population is shown in
table 3 and represented in standardized units in figure
1. There were two clusters identified in this population,
denoted as ‘favorable’, which represented 60% of the
population, and ‘adverse’ (40%). All metabolic variables
were significantly worse and there were a significantly
higher proportion of TSI people in the adverse cluster,
when compared with the favorable cluster. The major
contributors to cluster membership in descending order
were: SBP, DBP, waist circumference, fasting glucose
and triglycerides. HDL contributed little to explaining
cluster membership. Together these variables explained
64% of individual allocation to each particular cluster.
Disagreement between metabolic syndrome and MR
cluster membership occurred in 524 cases; 286 cases in
the favorable cluster were classified as having metabolic
syndrome, whereas 238 in the adverse cluster were not.
Aboriginal people when compared to TSI were more
likely to be in the adverse cluster but not be classified
as having metabolic syndrome (Additional file 2, Tables
1 and 2).
The multiple adjusted odds of elevated GGT were sig-
nificantly greater in moderate and risky drinkers
compared with non-drinkers (moderate: OR 2.3 [95%CI
1.6 - 3.2]; risky: OR 6.0 [4.4 - 8.2]), metabolic syndrome
compared with no metabolic syndrome (OR 2.7 [2.1 -
3.5]), adverse compared with favorable MR cluster (OR
3.4 [2.6 - 4.3]), diabetics compared with non-diabetics
(OR 2.1 [1.6 - 2.9]), and central and general overweight
(central: OR 2.3 [1.6 - 3.2]; general: OR 1.7 [1.4 - 2.2])
and obesity (central: OR 3.7 [2.5 - 5.6]; general: OR 1.7
[1.3 - 2.2]), when compared to normal weight.
Ethnicity and sex stratified analyses demonstrated strong
interactions between drinking and ethnicity and drinking
and sex, on the odds of elevated GGT. Aboriginal drinkers
were significantly more likely to have elevated GGT than
TSI drinkers (OR 2.2 [1.8 - 2.8], Table 4), and male drin-
kers were twice as likely to have elevated GGT as female
drinkers (OR 2.0 [1.2 - 3.5], Table 5). Moderate and risky
alcohol drinking did not interact with ethnicity or sex on
the odds of elevated GGT. There were no observed inter-
actions between metabolic risk and either ethnicity or sex
on elevated GGT.
When stratified by drinking status (Table 6), there was
no evidence of a multiplicative effect of moderate or
risky drinking with obesity or metabolic syndrome on
elevated GGT (interaction terms not shown). However,
in people with an adverse MR cluster profile, drinking
alcohol at risky levels was associated with a near 3-fold
increase in the log of the odds of elevated GGT when
compared with non-drinkers (OR 2.8 [1.6 - 4.9]).
A post-hoc analysis was performed in order to inves-
tigate any possible interfering effects of HDL on the
outcomes of the planned analysis, given that increases
in both HDL (improvement) and GGT (worsening)
result from increased alcohol consumption. Thus, we
re-performed all steps of the above analysis, beginning
with cluster analysis, excluding HDL. This process
yielded two clusters of similar proportions to our pre-
vious analysis, the variable means and the proportions
of Aboriginal and Torres Strait Islanders between clus-
ters were similar to the original analysis (data not
shown). Re-analysis of the individual effect of cluster
membership on elevated GGT gave similar results (OR
3.5 [95% CI 2. 9 - 4.2] compared with OR 3.4 [2.6 -
4.3] in the original analysis) and re-analysis of table 6
showed very similar results to those of the original
analysis, even after adjustment for HDL. The overall
effect of the cluster × alcohol interaction term was
also similar to the original analysis (OR 1.7 [95% CI
1.0 - 3.0]). When adjusted for HDL, the effect of the
interaction term was essentially unchanged (OR 1.8
[95% CI 1.1 - 3.2]).
Discussion
This study reported high population mean serum GGT
in both men (61.0 ± 74.2 U/L) and women (35.0 ± 40.4
U/L) that exceeded the highest population mean con-
centrations published previously by a study in north-
west Russia (Men: 43.8 ±60.5 U/L; Women: 28.3 ± 38.9
U/L) [29].
Table 3 Metabolic risk cluster profiles of Indigenous
adults across the studied rural far north Queensland
communities
Favorable cluster
(n = 1430, 60%)
Adverse cluster
(n = 955, 40%)
Mean or No. SD Mean or No. SD
Male * 634 (44.3%) 516 (54.0%)
Aboriginal * 912 (63.8%) 543 (56.9%)
Age ( years)* 31.8 13.5 45.6 14.2
WC (cm)* 89.10 14.76 104.63 14.48
Trigs (mmol/L)‡* 1.25 0.65 2.65 1.96
SBP (mmHg)* 120.24 12.63 145.53 18.25
DBP (mmHg)* 64.80 9.61 81.56 12.26
HDL (mmol/L)* 1.19 0.32 1.09 0.27
FPG (mmol/L)* 4.73 0.76 7.23 2.61
*significant difference of <0.001 between favorable and adverse MR cluster,
using t-test (for continuous variables with normal distribution, and Mann-
Whitney rank-sum test for continuous variables with non-normal distribution‡.
WC is waist circumference, Trigs is serum triglycerides, SBP is systolic blood
pressure, DBP is diastolic blood pressure, HDL is high density lipoprotein
cholesterol, FPG is fasting plasma glucose.
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Having an adverse metabolic profile was associated
with a 2.6 to 4.3-fold increase, and metabolic syndrome
with a 2.1 to 3.5-fold increase, in the odds of having
elevated GGT (≥50 U/L). A similar result for metabolic
syndrome has been shown within abstainers in this
cohort [13]. In this Indigenous population, an adverse
metabolic profile conferred 3 times the risk of elevated
GGT in risky drinkers than in abstainers. Interestingly,
this finding did not hold when using the metabolic syn-
drome classification in place of the MR cluster. Previous
studies in moderate alcohol drinkers and abstainers
have claimed additive effects of alcohol consumption
and BMI on elevated serum GGT and ALT [14,15], but
an interactive effect modeled using logistic regression
was not evident in this Australian indigenous
population.
Figure 1 A standardized comparison of metabolic risk factors between distinct Indigenous population clusters. This radial/spider plot
clearly shows the differences in metabolic risk factors between clusters. In the favorable compared to the adverse cluster, people have higher
HDL levels and lower systolic and diastolic blood pressures, triglycerides, glucose and waist circumference. Data are shown in standardized units
so that the magnitude of the difference between clusters can be compared between variables.
Table 4 Alcohol drinking and metabolic risk versus
elevated GGT (GGT ≥ 50 U/L) by ethnicity
Aboriginal TSI
Crude OR Adj. OR* Crude OR Adj. OR*
Alcohol Drinking
No 1.0 1.0 1.0 1.0
Yes 4.9 (3.6-6.7) 5.6 (3.9-8.0) 3.3 (2.1- 5.1) 2.2 (1.3-3.7)
Alcohol risk
No 1.0 1.0 1.0 1.0
Moderate 2.1 (1.4-3.2) 2.7 (1.7-4.1) 1.9 (1.1-3.2) 1.4 (0.8-2.5)
Risky 6.3 (4.6-8.7) 7.6 (5.2-11.1) 4.5 (2.9-7.1) 3.4 (1.9-5.9)
Metabolic syndrome †
No 1.0 1.0 1.0 1.0
Yes 2.1 (1.7-2.6) 2.7 (2.0-3.6) 2.8 (2.0-4.0) 2.2 (1.4-3.4)
MR cluster profile †
Favorable 1.0 1.0 1.0 1.0
Adverse 3.3 (2.6-4.1) 3.4 (2.5-4.5) 3.9 (2.7-5.7) 3.2 (2.0-5.0)
* Adjusted for age, sex, ethnicity, BMI, smoking, and PA level. † Risky drinking
was defined as > 6 drinks on any occasion or >4 drinks per day in males and
>4 drinks on any occasion or >2 drinks per day in female in the week prior to
the survey. Metabolic syndrome defined by IDF criteria: waist circumference
(≥94 cm in males and ≥80 for females), raised triglycerides (≥1.7 mmol/L),
reduced HDL (<1.03 in males or <1.29 in females), raised blood pressure
(systolic >130 mmHg or diastolic≥85 mmHg), and plasma glucose (≥5.6
mmol/L). Adverse MR (metabolic risk) cluster profile was obtained by EM
cluster analysis.
Table 5 Alcohol drinking and metabolic risk versus
elevated GGT (GGT ≥ 50 U/L) by gender
Female Male
Crude OR Adj. OR* Crude OR Adj. OR*
Alcohol drinking
No 1.0 1.0 1.0 1.0
Yes 2.7 (1.9-3.8) 3.5 (2.3-5.2) 5.4 (3.6-8.0) 5.9 (4.0-9.9)
Alcohol risk
No 1.0 1.0 1.0 1.0
Moderate 1.0 (0.6-1.9) 1.5 (0.9-2.6) 2.8 (1.8-4.5) 3.5 (2.1-5.9)
Risky 4.1 (2.9-5.8) 5.2 (3.4-8.0) 6.7 (4.4-10.0) 8.5 (5.3-13.5)
Metabolic syndrome †
No 1.0 1.0 1.0 1.0
Yes 2.7 (2.0-3.7) 3.1 (2.2-4.5) 2.1 (1.6-2.6) 1.8 (1.3-2.5)
MR cluster profile †
Favorable 1.0 1.0 1.0 1.0
Adverse 2.9 (2.1-3.9) 3.2 (2.2-4.7) 3.0 (2.3-3.8) 3.2 (2.3-4.4)
* Adjusted for age, ethnicity, BMI, smoking, and PA level. † Risky drinking was
defined as > 6 drinks on any occasion or >4 drinks per day in males and >4
drinks on any occasion or >2 drinks per day in female in the week prior to
the survey. Metabolic syndrome defined by IDF criteria: waist circumference
(≥94 cm in males and ≥80 for females), raised triglycerides (≥1.7 mmol/L),
reduced HDL (<1.03 in males or <1.29 in females), raised blood pressure
(systolic >130 mmHg or diastolic≥85 mmHg), and plasma glucose (≥5.6
mmol/L). Adverse MR (metabolic risk) cluster profile was obtained by EM
cluster analysis.
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These findings are novel and are significant in this
population. Although there are well known interactions
between BMI and drinking on GGT, to the authors
knowledge no published data exist regarding the interac-
tion between multiple co-existing metabolic risk factors
or different metabolic endophenotypes and alcohol
intake on liver enzymes. This is important as the inter-
actions may be much more severe for people with car-
dio-metabolic risk factors over and above overweight/
obesity. Moreover, we have tested the interactions with
two different methods for classifying cardio-metabolic
risk: (1) the IDF metabolic syndrome definition; (2) a
data driven approach to defining population metabolic
endophenotypes using the same variables. This depar-
ture from the controversial dichotomous classification of
the metabolic syndrome in capturing the population dis-
tribution of multiple metabolic risk factors is a major
strength of this study. A priori, we conceived that inter-
nationally used clinical cut-points for metabolic syn-
drome classification may not apply equally to Australian
Aboriginal and Torres Strait Islander peoples as there
metabolic endophenotypes are quite different (as evi-
denced in this cohort by Table 1) and thus the relations
between cardio-metabolic risk factors may vary. We
indeed demonstrated that there was a discrepancy (n =
524 cases) between clinical metabolic syndrome classifi-
cation and metabolic endophenotypes (clusters) that dif-
fered by ethnicity. Aboriginals were more likely to be
classified as not having metabolic syndrome but being
in the adverse MR cluster compared with Torres Strait
Islanders who were more likely to be classified as
metabolic syndrome but be in the favourable MR clus-
ter. This could be partially due to inappropriate waist
circumference cut-offs causing misclassification of IDF
metabolic syndrome which may in turn partly explain
the lack of interaction of alcohol drinking with meta-
bolic syndrome and obesity on elevated GGT. MR clus-
ters differed in their ethnic distribution, and cluster
membership was mostly explained by blood pressure
rather than abdominal obesity, which tends to explain
clustering in Caucasian populations. These different
metabolic (endo)phenotypes and their risk to future
health outcomes are deserving of further study. The
interactions of metabolic profile or body fat with alcohol
consumption on serum GGT may be dependent on
gene polymorphisms in the population that affect the
level of fat accumulation in liver cells, oxidative stress,
cytokine production, immune response and tissue fibro-
sis [30]. However, at present no genetic associations
with advanced NAFLD have been confirmed [31].
This is the first study of the associations of alcohol
intake and metabolic risk, their combined influence and
the potentially modifying role of gender and ethnic
background on elevated serum GGT in Indigenous Aus-
tralians. Although we have only studied an intermediate
outcome of liver function (GGT), to date very little has
been published on biochemical liver dysfunction or
NAFLD in Indigenous populations worldwide. The pre-
valence of elevated GGT in the communities studied
(overall 25.9%: males 36.1%, females 16.5%) were com-
parable to those reported in the Russian study. Similarly,
in an Atayal Aboriginal community in Taiwan, the
Table 6 Risk of elevated GGT with obesity, metabolic syndrome and metabolic risk cluster by drinking status
Non-drinkers (n = 791) Moderate drinkers (n = 552) Risky Drinkers † (n = 1183)
Crude OR Adj. OR* Crude OR Adj. OR* Crude OR Adj. OR*
Abdominal Obesity †
Normal 1.0 1.0 1.0 1.0 1.0 1.0
Overweight 1.4 (0.6-3.5) 1.5 (0.6-3.9) 1.5 (0.8-2.9) 1.9 (0.9-3.8) 1.8 (1.3-2.5) 3.2 (2.2-4.7)
Obese 2.0 (1.0-4.0) 2.6 (1.1-5.7) 1.7 (1.03-2.9) 4.5 (2.3-8.6) 1.5 (1.2-1.9) 4.2 (2.9-5.9)
BMI
<25 1.0 1.0 1.0 1.0 1.0 1.0
25-30 2.0 (1.1-3.8) 2.0 (1.01-3.9) 2.1 (1.2-3.6) 3.0 (1.6-5.6) 1.5 (1.2-2.0) 2.4 (1.7-3.3)
30+ 1.5 (0.8-2.8) 1.8 (0.9-3.6) 1.6 (0.9- 2.8) 2.7 (1.4-5.2) 1.4 (1.0-1.8) 2.9 (2.1-4.1)
Metabolic syndrome †
No 1.0 1.0 1.0 1.0 1.0 1.0
Yes 2.3 (1.4-3.8) 2.4 (1.3-4.1) 2.5 (1.6-3.9) 2.8 (1.7-4.6) 2.8 (2.2-3.5) 3.7 (2.8-5.0)
MR Cluster profile†
Favorable 1.0 1.0 1.0 1.0 1.0 1.0
Adverse 1.9 (1.2-3.1) 1.6 (0.9-2.8) 3.0 (1.9-4.8) 2.8 (1.6-4.9) 5.1 (3.9-6.6) 4.9 (3.7-6.7)
*Adjusted by age, sex, and ethnicity, smoking, and PA level. † Risky drinking was defined as > 6 drinks on any occasion or >4 drinks per day in males and >4
drinks on any occasion or >2 drinks per day in female in the week prior to the survey. Abdominal obesity defined using WHO WC gender specific criteria:
overweight being WC of 80-88 cm in females and 94-102 cm in males, while obesity being WC ≥88 cm in females and 102 cm in males. Metabolic syndrome
defined by IDF criteria: waist circumference (≥94 cm in males and ≥80 for females), raised triglycerides (≥1.7 mmol/L), reduced HDL (<1.03 in males or <1.29 in
females), raised blood pressure (systolic >130 mmHg or diastolic≥85 mmHg), and plasma glucose (≥5.6 mmol/L). Adverse MR (metabolic risk) cluster profile was
obtained by EM cluster analysis.
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overall prevalence of elevated GGT (defined in this
study as ≥61 U/L) was 22.4% (males 34.9%, females
10.7%). Over two thirds of this population were Aborigi-
nal and had an elevated GGT prevalence of 28.6% com-
pared with 8.8% in non-aboriginals [32]. It has been
suggested that the high prevalence of type 2 diabetes in
North American indigenous populations may indicate a
high prevalence of NAFLD [33], and despite a lack of
published data, this may also be true in Indigenous Aus-
tralians. Elevated serum GGT and diagnosed NAFLD
have also been shown to predict incident cardiovascular
events in the general population [34], and more strongly
in diabetics [34,35] and alcohol drinkers [34].
Almost 80% of Indigenous males and 59% of Indigen-
ous females in this study reported that they currently
drink alcohol. These percentages appear higher than
Australian population estimates for Indigenous Austra-
lians generally [36] and reflects near universal access to
alcohol from “wet” canteens in these remote commu-
nities in far north Queensland at the time of the study.
In these communities, drinking alcohol was associated
with a 3.6 to 6.2-fold increase in the chance of having
elevated GGT after adjustment for age, gender and eth-
nicity and the effect increased from moderate to risky
alcohol consumption. The association between alcohol
intake and GGT is well described [11] with modifica-
tions of this association by sex [37], ethnicity [38-40]
and age [41]. In these communities, the observed dou-
bling in risk of elevated GGT from drinking in males
compared with females, and in Aboriginal compared
with TSI peoples was directly related to the prevalence
of high risk alcohol consumption by males compared
with females and Aboriginal compared with TSI people.
Thus, irrespective of sex or ethnicity, people who drink
alcohol at risky levels have equivalent odds of elevated
GGT.
Limitations to this study include a possible downward
response bias to 7-day recall of alcohol consumption
[42], the sole use of GGT as an outcome and indicator
of NAFLD due to the limited ability to perform more
advanced investigations in very remote communities,
and a small degree of missing data on major exposure
variables that differentially occurred in participants who
were female, older and had lower blood pressure.
Conclusions
Taken together, drinking was most strongly associated
with elevated GGT in a dose dependent manner. Abori-
ginal men were at particularly high risk of elevated
GGT from drinking, due largely to the high prevalence
of risky drinking in this group. In this Indigenous popu-
lation, an adverse metabolic profile conferred 3 times
the risk of elevated GGT in risky drinkers than in
abstainers, independent of sex and ethnicity.
Interventions need to target modifiable community
determinants of both the population’s metabolic risk sta-
tus and risky alcohol drinking behaviour to achieve
greater reduction in population GGT levels. The effects
of such strategies on the rates of new diabetes, CHD
and stroke cases (major contributors to the Indigenous
health gap in Australia) require further investigation.
Additional material
Additional file 1: Expectation Maximisation Cluster analysis and
Partial Least Squares expanded methods. This file contains an
expanded discussion of the EM cluster and PLS analysis methods.
Additional file 2: Disagreement between IDF metabolic syndrome
classification and MR cluster membership. This file contains two
tables that show (1) the level of disagreement between the metabolic
syndrome classification and MR cluster membership, and (2) the
demographic and metabolic characteristics of cases in which
disagreement occurred.
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